These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 36268393)

  • 1. Efficacy, safety and cost-effectiveness of vonoprazan vs Proton Pump Inhibitors in reflux disorders and H. pylori eradication: A literature review.
    Shehryar M; Ahmad RU; Kareem HK; Khan L; Ashraf MF; Hassan A; Saeed S; Tareen HK; Nazir DA; Ashraf MA
    Ann Med Surg (Lond); 2022 Oct; 82():104760. PubMed ID: 36268393
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Review: A Japanese population-based meta-analysis of vonoprazan versus PPI for Helicobacter pylori eradication therapy: Is superiority an illusion?
    Dong SQ; Singh TP; Wei X; Yao H; Wang HL
    Helicobacter; 2017 Dec; 22(6):. PubMed ID: 28884937
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of Vonoprazan, a Novel Potassium-Competitive Acid Blocker, in Patients with Proton Pump Inhibitor-Refractory Acid Reflux.
    Akiyama J; Hosaka H; Kuribayashi S; Moriyasu S; Hisada Y; Okubo H; Watanabe K; Imbe K; Nagata N; Kojima Y; Yokoi C; Uemura N; Shimoyama Y; Kawamura O; Yamada M; Kusano M
    Digestion; 2020; 101(2):174-183. PubMed ID: 30897577
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness and safety of vonoprazan-based regimen for Helicobacter pylori eradication: A meta-analysis of randomized clinical trials.
    Yang C; Li S; Huang T; Lin H; Jiang Z; He Y; Yuan J; An H
    J Clin Pharm Ther; 2022 Jul; 47(7):897-904. PubMed ID: 35247003
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of the cost-effectiveness of using vonoprazan-amoxicillin-clarithromycin triple therapy for first-line Helicobacter pylori eradication.
    Kajihara Y; Shimoyama T; Mizuki I
    Scand J Gastroenterol; 2017 Feb; 52(2):238-241. PubMed ID: 27806639
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of Vonoprazan in
    Sugimoto M; Yamaoka Y
    Front Pharmacol; 2018; 9():1560. PubMed ID: 30697158
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is a Potassium-Competitive Acid Blocker Truly Superior to Proton Pump Inhibitors in Terms of
    Sue S; Maeda S
    Gut Liver; 2021 Nov; 15(6):799-810. PubMed ID: 33850058
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness and Safety of Vonoprazan versus Proton Pump Inhibitors for Second-Line Helicobacter pylori Eradication Therapy: Systematic Review and Meta-Analysis.
    Shinozaki S; Kobayashi Y; Osawa H; Sakamoto H; Hayashi Y; Lefor AK; Yamamoto H
    Digestion; 2021; 102(3):319-325. PubMed ID: 31914442
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vonoprazan versus Lansoprazole for the Initial Treatment of Reflux Esophagitis: A Cost-effectiveness Analysis in Japan.
    Habu Y
    Intern Med; 2019 Sep; 58(17):2427-2433. PubMed ID: 31178490
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness analysis of vonoprazan versus proton pump inhibitors in the treatment of reflux esophagitis in China.
    Wang Z; Sun R; Sheng Y; Qu S; Dong L; Wu B
    Ann Transl Med; 2022 Apr; 10(8):480. PubMed ID: 35571388
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of vonoprazan-based regimens compared with proton pump inhibitor-based regimens as first-line
    Kakiuchi T
    Front Pharmacol; 2023; 14():1216433. PubMed ID: 37538185
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Triple-Drug Blister-Packaged Drug with Vonoprazan Improves First-Line Eradication of Helicobacter pylori in Elderly Patients: A Retrospective Propensity Score-Matched Cohort Study.
    Nishida T; Tsujii Y; Okamoto A; Tomita R; Higaki Y; Osugi N; Sugimoto A; Takahashi K; Mukai K; Nakamatsu D; Matsubara T; Hayashi S; Yamamoto M; Nakajima S; Fukui K; Inada M
    Digestion; 2020; 101(5):608-614. PubMed ID: 31288235
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vonoprazan-Based Regimen Is More Useful than PPI-Based One as a First-Line
    Maruyama M; Tanaka N; Kubota D; Miyajima M; Kimura T; Tokutake K; Imai R; Fujisawa T; Mori H; Matsuda Y; Wada S; Horiuchi A; Kiyosawa K
    Can J Gastroenterol Hepatol; 2017; 2017():4385161. PubMed ID: 28349044
    [No Abstract]   [Full Text] [Related]  

  • 14. Efficacy of vonoprazan for initial and maintenance therapy in reflux esophagitis, nonerosive esophagitis, and proton pump inhibitor-resistant gastroesophageal reflux disease.
    Gotoh Y; Ishibashi E; Honda S; Nakaya T; Noguchi C; Kagawa K; Murakami K
    Medicine (Baltimore); 2020 Mar; 99(11):e19520. PubMed ID: 32176102
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Ameliorating Effect of Switching to Vonoprazan: A Novel Potassium-Competitive Acid Blocker in Patients with Proton Pump Inhibitor Refractory Non-Erosive Reflux Disease.
    Abe Y; Koike T; Saito M; Okata T; Nakagawa K; Hatta W; Asanuma K; Uno K; Asano N; Imatani A; Masamune A
    Digestion; 2021; 102(3):480-488. PubMed ID: 32062650
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vonoprazan versus conventional proton pump inhibitor-based triple therapy as first-line treatment against Helicobacter pylori: A multicenter retrospective study in clinical practice.
    Shichijo S; Hirata Y; Niikura R; Hayakawa Y; Yamada A; Mochizuki S; Matsuo K; Isomura Y; Seto M; Suzuki N; Suzuki H; Yamamoto S; Sugimoto T; Omae T; Okamoto M; Watabe H; Togo G; Takano N; Fukui K; Ito Y; Koike K
    J Dig Dis; 2016 Oct; 17(10):670-675. PubMed ID: 27534444
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The efficacy and safety of vonoprazan in quadruple therapy for
    Zhuang X; Jiang H; Jin D; Sun M; Wang Z; Wang X
    Gastroenterol Rep (Oxf); 2024; 12():goae036. PubMed ID: 38628396
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of Vonoprazan for Proton Pump Inhibitor-Resistant Reflux Esophagitis.
    Hoshino S; Kawami N; Takenouchi N; Umezawa M; Hanada Y; Hoshikawa Y; Kawagoe T; Sano H; Hoshihara Y; Nomura T; Iwakiri K
    Digestion; 2017; 95(2):156-161. PubMed ID: 28190016
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systematic review with meta-analysis: Vonoprazan, a potent acid blocker, is superior to proton-pump inhibitors for eradication of clarithromycin-resistant strains of Helicobacter pylori.
    Li M; Oshima T; Horikawa T; Tozawa K; Tomita T; Fukui H; Watari J; Miwa H
    Helicobacter; 2018 Aug; 23(4):e12495. PubMed ID: 29873436
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.